Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

GHRP-2: does it work, is it legal, and what does it cost?

Triggers growth hormone via the hunger hormone (ghrelin) receptor; small randomized trials measured hormones and appetite; a diagnostic in Japan; WADA banned.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about GHRP-2
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Not eligible for compounding

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [8] [9] See legal status

What does it cost?Not available through licensed US channels.
Side effects?Increased hunger (36% increase in food intake in a controlled study). Transient flushing, warmth, and sweating after intravenous dosing. Rise in cortisol and prolactin with each dose. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is GHRP-2?

GHRP-2 (pralmorelin) is a synthetic six amino acid peptide that stimulates growth hormone release by activating the ghrelin (GHS-R1a) receptor, the receptor for the body's hunger hormone. Small randomized trials show it raises growth hormone and increases food intake, and other short human studies show it raises cortisol and prolactin; it is approved in Japan as a diagnostic test for growth hormone deficiency, but it has no approved therapeutic use anywhere and no randomized trial has tested it for muscle growth, fat loss, or the other uses it is sold for. FDA placed it in 503B Category 2 (ingredients flagged for significant safety risks in outsourcing facility compounding) in September 2023 for injectable and nasal routes, it has no 503A listing (the pathway for pharmacies compounding for individual patients), and it is prohibited by WADA.

GHRP-2 is a synthetic hexapeptide growth hormone secretagogue (ghrelin receptor agonist). It is also known as Growth hormone releasing peptide-2, Pralmorelin, KP-102, GHRP 2, D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2.

How does it work?

GHRP-2 binds the growth hormone secretagogue receptor (GHS-R1a), the same receptor as ghrelin, on pituitary somatotrophs and hypothalamic neurons. Activation triggers a pulse of growth hormone that is additive with GHRH, and it also raises ACTH, cortisol, and prolactin. Because it mimics ghrelin it increases hunger. It contains D amino acids and an unnatural amino acid (D-beta-naphthylalanine), which resist enzymatic breakdown.

Key facts
ClusterMetabolic and growth hormone axis
RoutesIntravenous bolus or infusion (diagnostic and research studies); Intranasal (research studies); Subcutaneous infusion (appetite studies); Subcutaneous injection (as sold, not from published trials)
Conditions studiedGrowth hormone deficiency and GH secretagogue use
Recordv3, reviewed, verified Sep 30, 2026

What does the evidence say about GHRP-2?

Evidence: Human RCT evidenceGrade assigned per the methodology.

Several small randomized trials have tested GHRP-2 in people. A double blind, randomized, placebo controlled crossover in 19 lean and obese adults found a subcutaneous infusion raised food intake in a dose dependent way, by about a third at the higher dose, and two randomized trials in critically ill adults (26 and 33 patients) found infusions raised growth hormone and IGF-1. A randomized sleep study in 7 healthy men found growth hormone and prolactin rose with no change in slow wave sleep. These trials measured appetite, hormone, and metabolic responses over hours or days; no randomized trial has tested GHRP-2 for muscle growth, fat loss, or any other use it is sold for.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials485
Human observational studies5103
Animal studies0n/a
All indexed studies9188

Human evidence

Pihoker 1995 (n = 34 short children) showed intravenous and intranasal GHRP-2 produced dose dependent GH release, with 1 ug/kg intravenously being a reliable stimulus. Arvat 1997 compared GHRP-2 and hexarelin in healthy adults and found both raised GH more than GHRH and also raised prolactin, ACTH, and cortisol. Moreno-Reyes 1998 gave 7 healthy men an intravenous injection of GHRP-2 or saline in randomized order during sleep; GH and prolactin rose and slow wave sleep did not change. Van den Berghe 1997 used a randomized crossover design in 26 critically ill adults, comparing overnight infusions of placebo, GHRH, GHRP-2, and the combination, and found GHRP-2 raised mean GH concentrations 4 to 6 fold. Van den Berghe 2002 randomly assigned 33 critically ill men to 5 days of placebo, GHRP-2 alone, or GHRP-2 combined with other releasing hormones and measured endocrine and metabolic markers; GHRP-2 alone restored GH secretion and IGF-1. Laferrere 2005 gave 7 healthy men a 1 ug/kg per hour subcutaneous infusion of GHRP-2 or saline and measured a 35.9% increase in ad libitum food intake; the abstract does not state randomization or blinding. Laferrere 2006 tested the same question in a double blind, randomized, placebo controlled crossover in 19 adults (10 lean, 9 obese) and found food intake rose dose dependently, by 33.5% at the higher dose, regardless of obesity status. Chihara 2007 (n = 62 adults, plus controls) validated a 100 ug intravenous test for adult GH deficiency. Long term outcome data in adults are absent.

Animal evidence

GHRP-2 was developed from the original GHRP-6 series in rats and shown to release GH in rats, dogs, and primates and to act synergistically with GHRH. Rodent work established the ghrelin receptor as its target. Animal data are pharmacological rather than disease model based.

Key studies

Indexed studies of GHRP-2
StudyDesign and populationOutcomeGrade
Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake2006 PMID 16861611Double blind, randomized, placebo controlled crossover over three visits, subcutaneous infusion at two dose levelsn = 19 Healthy, weight stable adults (10 lean, 9 obese)Ad libitum food intake rose dose dependently, by 10.2% at the low dose and 33.5% at the high dose versus placebo, regardless of obesity status; serum GH rose dose dependently. Appetite and hormone physiology, not a clinical outcomeEvidence: Human RCT evidence
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion1997 PMID 9024260Randomized crossover of overnight infusions (placebo, GHRH, GHRP-2, or GHRH plus GHRP-2) over 2 consecutive nightsn = 26 Critically ill adultsGHRP-2 raised mean GH concentration 4 to 6 fold and serum IGF-1 by about 61% within 24 hours without changing cortisol; hormone endpoints onlyEvidence: Human RCT evidence
The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone2002 PMID 12030918Randomized, placebo controlled trial of 5 days of infusion: placebo, GHRP-2 alone, GHRP-2 plus TRH, or GHRP-2 plus TRH plus GnRHn = 33 Men with prolonged critical illnessGHRP-2 alone reactivated GH secretion and normalized IGF-1; the metabolic effects seen with the combinations were absent with GHRP-2 alone; endocrine and metabolic markers onlyEvidence: Human RCT evidence
Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation1998 PMID 9612233Intravenous GHRP-2 or saline given in randomized order during sleepn = 7 Healthy young menGH and prolactin rose after each GHRP-2 injection; no effect on slow wave sleepEvidence: Human RCT evidence
Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature1995 PMID 7559885Dose response pharmacology studyn = 34 Children with short statureIntravenous 1 ug/kg and intranasal doses produced dose dependent GH release; intravenous route was the more reliable diagnostic stimulusEvidence: Human observational evidence
Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH1997 PMID 9285939Crossover pharmacology study in healthy volunteersHealthy young adultsGHRP-2 and hexarelin released more GH than GHRH and also raised prolactin, ACTH, and cortisolEvidence: Human observational evidence
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men2005 PMID 15699539Saline controlled infusion study; the abstract does not state randomization or blindingn = 7 Healthy lean menA 1 ug/kg per hour subcutaneous infusion increased ad libitum food intake by 35.9% versus salineEvidence: Human observational evidence
A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency2007 PMID 17609397Diagnostic validation studyn = 62 Adults with suspected GH deficiency and healthy controls in JapanA 100 ug intravenous GHRP-2 test with a peak GH cutoff of 9 ng/mL discriminated severe adult GH deficiencyEvidence: Human observational evidence
Growth hormone-releasing peptide (GHRP)1998 PMID 9893708Narrative review by the discoverer of the GHRP seriesAnimal and human pharmacology of GHRP-6, GHRP-2, and related peptidesSummarizes receptor mechanism, synergy with GHRH, and human GH release dataEvidence: Human observational evidence

Conditions studied

Conditions with evidence for GHRP-2
ConditionGradeNote
Growth hormone deficiency and GH secretagogue useNot gradedTesamorelin is FDA approved to reduce abdominal fat in HIV associated lipodystrophy, and sermorelin was previously approved for pediatric GH deficiency. Ipamorelin, CJC-1295, GHRP-2, GHRP-6, hexarelin, and MK-677 raise growth hormone in small human studies but are not approved for any indication and are WADA prohibited.

Is GHRP-2 legal in the United States?

Regulatory: Not eligible for compoundingWADA: WADA prohibited

FDA and compounding status

Not FDA approved for any use. For 503A pharmacies, FDA lists GHRP-2 in Category 3, meaning it was nominated without enough support for FDA to evaluate it. It gets no protection under FDA's interim policy and is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it. For 503B outsourcing facilities, FDA placed GHRP-2 for injectable and nasal routes in Category 2 on September 29, 2023. FDA cited immunogenicity risk, an unnatural amino acid that complicates characterization, and reports of serious adverse events. GHRP-2 for other routes is in 503B Category 1. The only form within FDA's interim policy is a non-injectable, non-nasal product made by an outsourcing facility that meets the policy's conditions. As of the last verification date there is no federal basis for a compounded injectable or nasal form.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

  1. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

  2. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

  3. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 and its derivatives, including TB-500, and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

  4. FDA

    FDA places GHRP-2, GHRP-6, and ipamorelin in 503B Category 2

    On September 29, 2023 FDA added growth hormone releasing peptide-2 (GHRP-2, for injectable and nasal routes), GHRP-6, and ipamorelin acetate to Category 2 under the 503B interim policy, citing immunogenicity risk from aggregation and peptide related impurities and, for GHRP-2, reports of serious adverse events. Outsourcing facilities may not compound a substance while it is in 503B Category 2. All three remain listed on the FDA page current as of April 22, 2026.

Full tracker for GHRP-2 or the category-wide tracker.

Email me when GHRP-2's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of GHRP-2 used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Diagnostic use only: single intravenous doses of 1 ug/kg in children (Pihoker 1995) and 100 ug in adults (Chihara 2007), or a 1 ug/kg per hour subcutaneous infusion in the food intake study (Laferrere 2005). No chronic therapeutic dose has been established in human literature; subcutaneous regimens sold online are not from any published trial.

Routes reported

Routes of administration reported for GHRP-2
#Route
1Intravenous bolus or infusion (diagnostic and research studies)
2Intranasal (research studies)
3Subcutaneous infusion (appetite studies)
4Subcutaneous injection (as sold, not from published trials)

What are the side effects and interactions of GHRP-2?

Side effects

Side effects reported for GHRP-2
#Reported side effect
1Increased hunger (36% increase in food intake in a controlled study)
2Transient flushing, warmth, and sweating after intravenous dosing
3Rise in cortisol and prolactin with each dose
4Reduced insulin sensitivity and higher blood glucose (FDA cites reports of increased insulin requirements)
5FDA notes reports of pancreatitis, infection, and death in critically ill study subjects without established causality
6Water retention and numbness or tingling reported with growth hormone secretagogues generally

Interactions

Interactions reported for GHRP-2
#Interaction
1Insulin and oral diabetes medications: GH secretagogues raise blood glucose and can increase insulin requirements
2Glucocorticoids: GHRP-2 raises ACTH and cortisol, so stacking adds to steroid exposure
3GHRH analogs (sermorelin, CJC-1295, tesamorelin): synergistic GH release, untested for long term safety
4No formal human drug interaction studies exist

Contraindications

Contraindications for GHRP-2
#Contraindication
1Active cancer (GH and IGF-1 stimulation is a theoretical tumor growth concern)
2Diabetes or impaired glucose tolerance without monitoring
3Pregnancy and breastfeeding (no data)
4Athletes subject to WADA testing (prohibited at all times under S2)

How do people access GHRP-2 legally?

Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.

  • Not available

    Not available as an FDA approved product; FDA placed GHRP-2 in 503B Category 2 on September 29, 2023 and it has no 503A nomination or listing.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare GHRP-2

What's actually offered, and what that means for you

FDA has found compounding pharmacies offering GHRP-2 anyway. [12] [13]

Being offered does not change the legal status of GHRP-2. GHRP-2 is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [8] [9]

What FDA found

  • April 2020: FDA named GHRP-2 among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [13]
  • February 2019: FDA told a 503A pharmacy that drugs it compounded from GHRP-2 and GHRP-6 were not eligible for section 503A exemptions, and cited insanitary sterile conditions. [12]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [14] [15] [16] [17] [18]

What that means for you

  • A pharmacy that compounds GHRP-2 is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [14] [15]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [18]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [19]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [20] [21]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, GHRP-2 is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [10]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound GHRP-2, with or without a prescription. [9]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [22] [23] [24]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [24] [25] [26]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [18] [27] [28] [29] [30] [31]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [18]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [22]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [26]
  • Pharmacy: Is this made for me on a prescription written in my name? [25]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [24] [26]
  • Prescriber: What is the legal basis for a pharmacy to compound GHRP-2? Is it FDA approved or on the 503A bulks list? [9] [18]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [26]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [19]

Frequently asked questions

Is GHRP-2 legal in the United States?

It is not an FDA approved drug and has no federal basis to be compounded (custom-made by a pharmacy). FDA placed GHRP-2 in 503B Category 2 (substances with significant safety risks, under the rules for large outsourcing facilities) on September 29, 2023 for injectable and nasal use, and it has no 503A nomination (the pathway for pharmacies compounding for individual patients), so no licensed pharmacy can compound it. Possession is not a crime, but selling it for human use is unlawful: products sold as research chemicals are unapproved drugs. In Japan it is approved only as a diagnostic test for growth hormone deficiency. [4] [8] [9] [11]

Does GHRP-2 work for muscle growth or fat loss?

Nobody has tested that. The randomized trials of GHRP-2 measured growth hormone, appetite, and hormone or metabolic markers over hours or days, in healthy volunteers or critically ill patients, not muscle, strength, or fat. GHRP-2 reliably releases a pulse of growth hormone and raises GH more than GHRH alone. There is no randomized trial measuring body composition, strength, or fat loss with repeated dosing in adults, so any such benefit is extrapolated from growth hormone physiology rather than shown. [1] [2] [6] [7]

What are the side effects of GHRP-2?

The best documented effect is hunger: in a double blind, randomized crossover in 19 lean and obese adults, a subcutaneous infusion raised food intake by about a third at the higher dose. Each dose also raises cortisol and prolactin. FDA's Category 2 rationale cites reports of increased insulin requirements, pancreatitis, infection, and deaths in critically ill study subjects, without established causality. Flushing and sweating are common after intravenous doses. [2] [6] [8]

How is GHRP-2 taken?

In published studies it was given intravenously as a single injection or an infusion, under the skin as an infusion lasting several hours, and intranasally in one pediatric study. Products sold online are subcutaneous injection vials used on repeated schedules that no published human trial has tested. [1] [4] [6]

How much does GHRP-2 cost?

There is no licensed US price because no pharmacy can lawfully compound it. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [8] [11]

Is GHRP-2 banned by WADA?

Yes. Growth hormone secretagogues, including growth hormone releasing peptides such as GHRP-2, are prohibited at all times under section S2 of the WADA Prohibited List. GHRP-2 is one of the peptides most commonly detected in doping controls. [10]

GHRP-2 vs GHRP-6: what is the difference?

Both are synthetic hexapeptides acting on the ghrelin receptor. GHRP-2 is generally reported as the more potent GH releaser and is the one validated as a diagnostic test, while GHRP-6 was the original compound and produces the stronger hunger response in most reports. Both raise cortisol and prolactin, both are in FDA 503B Category 2 since September 2023, and both are WADA prohibited. Neither has long term human trial data. [2] [5] [8]

Is GHRP-2 the same as pralmorelin?

Yes. Pralmorelin (KP-102) is the international nonproprietary name for GHRP-2. Under that name it is approved in Japan as a single dose intravenous diagnostic test for growth hormone deficiency, which is the only regulatory approval the molecule holds anywhere. [4]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Pihoker C et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab 1995PubMed 7559885, 1995
  2. [2]Arvat E et al. Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man. Peptides 1997PubMed 9285939, 1997
  3. [3]Laferrere B et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005PubMed 15699539, 2005
  4. [4]Chihara K et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol 2007PubMed 17609397, 2007
  5. [5]Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci 1998PubMed 9893708, 1998
  6. [6]Laferrere B et al. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring) 2006PubMed 16861611, 2006
  7. [7]Van den Berghe G et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002PubMed 12030918, 2002
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  9. [9]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  10. [10]WADA Prohibited List, section S2 peptide hormones, growth factors, related substances and mimeticsWADA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). GHRP-2: evidence, legality, and access. https://peptideagent.ai/peptides/ghrp-2
HTML link
<a href="https://peptideagent.ai/peptides/ghrp-2">GHRP-2: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.